A better prescription for drug-development financing

Nature Biotechnology

Volumn 25, Issue 8, 2007, Pages 859-866

  Kessel, Mark ^a   Frank, Frederick ^b  

^a Symphony Capital   (United States)

^b LEHMAN BROTHERS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOTECHNOLOGY; DRUG PRODUCTS; MARKETING;

CLINICAL PROGRAMS; DRUG DEVELOPMENT; PUBLIC MARKETS;

FINANCE;

BIOTECHNOLOGICAL PROCEDURES; DRUG COST; DRUG DEVELOPMENT; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG RESEARCH; FINANCIAL MANAGEMENT; LICENSING; PRESCRIPTION; PRIORITY JOURNAL; REVIEW;

CAPITAL FINANCING; DRUG DESIGN; DRUG INDUSTRY; INVESTMENTS; MODELS, ORGANIZATIONAL; PHARMACEUTICAL PREPARATIONS; RESEARCH; UNITED STATES;

EID: 34547778902     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt0807-859     Document Type: Review

References (6)

1. Kaitin, K.I. (ed.) Cost to develop new biotech products is estimated to average $1.2 billion. Tufts Center for the Study of Drug Development Impact Report, vol. 8 (Tufts Center for the Study of Drug Development, Boston, Massachusetts, November/December 2006)
2. Bouchie, A.J. Optioning your drugs. The Scientist 20, 76 (2006).
3. Schiff, L. & Murray, F. Biotechnology financing dilemmas and the role of special purpose entities. Nat. Biotechnol. 22, 271-277 (2004).
4. Ransom, J. A reprise for collaborative financing in biotech. Nat. Biotechnol. 24, 873-874 (2006).
5. 〈http://www.pharmadd.com/archives/July%202006/ MM%20Deals%20Bring%20Value.asp〉
6. Longman, R. No dilution necessary: the promise of project financing. In Vivo 23, 12 (2005).